The company's decision to advance both programs suggests confidence that the GLP-1/amylin dual pathway represents the future of obesity pharmacotherapy, with room for multiple formulations serving different patient preferences
Grivennikov, S
How a Houston Podiatrist Uses BPC-157 A Complete Treatment Approach After treating thousands of patients in Houston, the question I always start with isn't "what's wrong with your foot?" It's "what do you want to be able to do?" Because the treatment plan that gets a 65-year-old back to morning walks looks different from the one that gets a 35-year-old back on the marathon course even if the diagnosis is identical
A change in clarity is generally the most reliable early sign, since a properly reconstituted and well-stored solution should remain visually consistent throughout its usable life
There arent severe side effects associated with nootropics in peptides
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
